• Smits, M. M., & Van Raalte, D. H. (2021). Safety of semaglutide. Frontiers in endocrinology, 12, 645563. https://pubmed.ncbi.nlm.nih.gov/34305810/
• Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019). Semaglutide as a promising antiobesity drug. Obesity Reviews, 20(6), 805-815. https://pubmed.ncbi.nlm.nih.gov/30768766/
• Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2023). Semaglutide for the treatment of obesity. Trends in cardiovascular medicine, 33(3), 159-166. https://pubmed.ncbi.nlm.nih.gov/34942372/
• Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023). Semaglutide for the treatment of overweight and obesity: a review. Diabetes, Obesity and Metabolism, 25(1), 18-35. https://pubmed.ncbi.nlm.nih.gov/36254579/
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., ... & Vilsbøll, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/